Russian NMOSD patients under the microscope: no new drug, just Real-World data
NCT ID NCT07247292
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study is not testing a new treatment. Instead, it observes how 100 adults with a rare autoimmune disease called NMOSD are managed in everyday Russian clinics. Researchers will collect medical records and follow patients over time to understand their symptoms, treatments, and outcomes. The goal is to learn more about real-world care patterns, not to offer a cure or new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Novosibirsk, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One-shot gene editor aims to correct a brain disorder at its source
- Hackathon for the undiagnosed: mayo clinic launches repository to crack rare disease cases
- Biobank aims to unlock genetic secrets of rare diseases
- AI could shorten the long road to a rare disease diagnosis
- New hope for kids with MVID: drug aims to cut diarrhea and IV needs
- Scientists launch study to map rare baker gordon syndrome from childhood to adulthood